• Search for:
    25Oct, 2026
    THE PHARMACOVIGILANCE ADVISORY COMMITTEE (PVAC)

    OPERATING GUIDELINES FOR
    THE PHARMACOVIGILANCE ADVISORY COMMITTEE (PVAC)

    Pharmacovigilance Advisory Committee was created in the purpose of Pharmacovigilance System Operating in Cambodia. The committee will consist of senior officials from Ministry of Health (MOH), University of Health Sciences, National Hospitals, and National Center in Health Sector.

    Download File
    3Oct, 2025
    Guidelines on the Pharmacovigilance System for National Programs in Public Health Interventions

    Guidelines on the Pharmacovigilance System for National Programs in Public Health Interventions aim to ensure the safety and quality of medicines. Their purpose is to guarantee medicine safety by providing reliable and timely information on safety issues, thereby promoting pharmacovigilance activities nationwide and encouraging participation in WHO programs to monitor medicine safety at the international level.

    These pharmacovigilance guidelines for national programs in public health interventions were developed through consultations with international pharmacovigilance experts and national public health intervention programs, including the National Malaria Center, the National Tuberculosis and Hansen’s Disease Center, the National Center for HIV/AIDS, Dermatology and STDs, and the National Immunization Program.

    Download File
    3Sep, 2025
    CAMBODIAN PHARMACOVIGILANCE CENTER IN AMFm PROJECT PHASE 1

    The Department of Drugs and Food/Essential Drug Bureau (DDF/EDB) has applied and successfully qualified for Global Fund (GF) grant for strengthening health system (HSS) under the National Malaria Control Program (CNM) for the containment of malaria resistant parasites in malaria endemic provinces in Cambodia. The project, Affordable Medicines Facility-malaria (AMFm), as the name suggests, aims at introducing cheaper artemisinin combination therapy (ACTs) in fixed dose combination (FDC) with the aim of driving out of the market oral artemisinin monotherapies and its derivatives which are thought to contribute to the currently observed emergence of malaria parasites tolerant to artemisinin therapy, the only remaining effective and safe medicine for the treatment of uncomplicated malaria caused by Plasmodium falciparum parasite. A large part of DDF work plan under the AMFm project consists of activities that are related to assuring the quality and efficacy of essential medicines; with a particular focus on the long term safety of the new ACTs to patients.

    Download File